Menu
Home
KYSLECEL™
KYSLECEL™
FAQs
Patient Info Sheet
Physician Instructions
R&D
R&D
Our Pipeline
Relevant Publications
Therapeutic Focus
Collaborators
About
About
Mission, Values, Ethics
News
Our Team
Investors
Investors
Board of Directors
Contact
Contact
Career
Home
KYSLECEL™
FAQs
Patient Info Sheet
Physician Instructions
R&D
Our Pipeline
Relevant Publications
Therapeutic Focus
Collaborators
About
Mission, Values, Ethics
Our Team
News
Notice of Privacy Practices
Investors
Board of Directors
Contact
Career
MENU
Now Hiring - View Here
Transformational cell therapies for patients with serious diseases.
OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.
Matthew Lehman,
Chief Executive Officer (Koligo
Therapeutics Inc.) and
Executive Director
Proven biotech & cell therapy executive
NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
Clinical research & manufacturing scale-up expertise
MS Columbia; BA Louisville
VIEW BIO
Stuart Williams, PhD,
Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director
Division chief, Bioficial Heart, Cardiovascular Innovation Institude
300+ publications & 16 issued US patents in cell & tissue engineering
Experienced academic-industry partner: founded three biotech companies
PhD cell biology University of Delaware, postdoc Yale School of Medicine
VIEW BIO